Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Articles

AI and machine learning are helping pharmaceutical scientists more efficiently develop innovative and novel treatments for a range of disease areas.

Integrating AI and Machine Learning in Drug Discovery and Development

AI and machine learning may be the ideal tools to evaluate patient data and predict ideal treatment options.

The Transformative Potential of AI to Enhance Patient Treatment

The CRDMO’s new facility will double chemistry capacity for drug discovery research and scale-up projects.

Jubilant Biosys Announces New Facility in India

Videos

Dr. Jennifer Levin Carter, founder and CEO of Medzown, discusses what makes precision medicine different from personalized medicine and what how challenges faced in this evolving field can be overcome. 

Personalized Medicine Vs. Precision Medicine

Arthur Tzianabos, CEO, Lifordi Immunotherapeutics, spoke with PharmTech about the company’s immune-directed antibody-drug conjugate (ADC) strategy, the benefits of VISTA-targeted ADCs in drug delivery, and Lifordi’s plans at the JP Morgan Healthcare Conference. 

The Benefits of an Immune-Directed ADC Strategy 

Elisabeth Gardiner, CSO of Tevard Biosciences, discusses how transfer RNA is impacting the development of gene therapies for diseases with unmet needs.

Gene Therapy, Rare Diseases, and Transfer RNA

The company’s new AI agent automates labor-intensive processes involved in trial document management.

Medable Presents AI Agent for Automating Trial Master File Processes at JP Morgan Healthcare Conference

The move brings Amgen first-in-class, small molecule-targeted protein degraders for oncology. 

Amgen Acquires UK Biotech Dark Blue Therapeutics

Laine Mello, director of marketing at Ecolab Bioprocessing, reflects on how the use of digital technologies expanded in the pharma industry in 2025 and how new complex molecules will continue to drive innovation in 2026.

Industry Outlook 2026: Trends Transitioning from 2025 into 2026 

Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals will receive advisory services and funding from UKRI Innovate UK and Canada’s NRC IRAP to develop next-generation genetic medicines.

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development